Somatostatin, a hypothalamic peptide initially reported to suppress pituitary growth hormone secretion ( l ) , has been found to possess extra-pituitary effects. The secretions of gastrointestinal hormones such as gastrin (2) and secretin (3) have been reported to be inhibited by somatostatin as have the release of the pancreatic glucoregulatory hormones, insulin (4), and glucagon ( 5 ) . The ability of somatostatin to inhibit hormone secretion in various endocrine tissues has prompted the suggestion that this peptide may act on a common step in secretory processes (6).Calcium ion is recognized as an essential requirement for the secretion of most, if not all, peptide hormones (7) and recent evidence suggests that somatostatin's inhibition of glucose-induced insulin release may be related to the divalent cation (8,9). In an effort to explore the relationship between somatostatin and calcium further, we have investigated the inhibitory action of somatostatin on glucose and ionophore A23 187induced insulin secretions in the isolated, perfused dog pancreas.Methods and materials. Pancreases were obtained from mongrel dogs (17-25 kg) and perfused according to procedures previously described (1 0). Normal perfusate consisted of Krebs-Ringer bicarbonate buffer containing 4 % dextran and 75 mg% glucose. The ionic concentrations of this medium in mEq/liter are: Na+, 143; K+, 5.9; Ca2+, 2.5; 1.2; and HC03-, 24.6. Cyclic somatostatin (Bachem, Inc.) and ionophore A23187 (generously supplied by Dr. Robert Hamill, Eli Lilly and Co.) were added as required. A23 187 was dissolved in ethanol before being added to the desired perfusate (11).